The Quantitative Pharmacology Network

March 20, 2017
No Comments

The American Society for Pharmacology and Therapeutics (ASCPT) is enacting its 5-year strategic plan through member-lead scientific networks. The Quantitative Pharmacology Network, chaired by Anne Heatherington from Pfizer, has led the “Influence and Impact Initiative.” The goal of the initiative is to compile a compendium of high impact examples of applications of Quantitative Pharmacology to drive decisions in the drug development process and to support ASCPT members and other scientists to convey the role of Quantitative Pharmacology in driving critical decisions. Included in the compendium is  the work entitled “Preclinical to clinical forecasting in tuberculosis drug development using a translational pharmacometric approach “ contributed by Professor Ulrika Simonsson from Uppsala University, Sweden as part of work from PreDiCT-TB. In this case example, clinical trial simulations of Phase 2 studies are predicted based on only pre-clinical information as an example of PKPD modeling to support decision making in TB drug development. The work was presented at the scientific meeting of the Quantitative Pharmacology Network at the ASCPT Annual Meeting in Washington DC in March 2017 and is part of a compendium of case examples of high impact examples for drug development which can be found in the ASCPT 2017 App in the schedule – within the Thursday March 16 QP Network Meeting 3.15-5.15 pm section.

Consortium Partners

PreDiCT-TB brings together twenty-one leading European research partners in tuberculosis from both Industry and Academia

View More

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115337, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.

The communication contained within this site reflects the author’s view and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained therein.